Introduction {#sec1-1}
============

Obstructive sleep apnea (OSA) is an important, yet inadequately diagnosed public health problem that is characterized by repetitive collapse of the upper airway during sleep.\[[@ref1]\] It has been reported that OSA affects up to 5% of the world\'s population\[[@ref2]\] with a prevalence of prevalence of 4% in males and 2% in females\[[@ref3]\] aged between 30 years and 60 years of age. The available literature on the prevalence of this disorder in the Indian population is limited. A study performed by Sharma *et al*.\[[@ref4]\] in an urban setting estimated the prevalence of OSA to be 13.7%.

OSA is a predisposing factor for multiple comorbidities such as hypertension, cardiovascular consequences (including sudden death),\[[@ref5][@ref6]\] ischemic heart disease, stroke\[[@ref7][@ref8][@ref9][@ref10][@ref11][@ref12]\], and uncontrolled diabetes. An increased risk of road traffic accidents has also been reported in patients suffering from OSA.\[[@ref13]\] The awareness about this disorder and its associated outcomes is on the rise among patients and clinicians. This has resulted in ever-increasing referrals to sleep clinics for diagnostic evaluation but the infrastructure to support the demand for rising sleep studies has not escalated commensurately.\[[@ref14]\] The "gold standard" test for diagnosis of sleep disorders is a conventional, fully supervised, in-laboratory polysomnography (PSG).\[[@ref15]\] With the limited availability of accredited sleep laboratories, certified sleep technologists, and complete polysomnography (CPSG) equipment in many countries, long waiting times and high costs of testing are inevitable.\[[@ref14]\]

In view of the above mentioned reasons, several alternative diagnostic tools such as sleepiness questionnaires, clinical decision rules,\[[@ref16]\] portable monitors (PMs), actigraphs, and peripheral arterial tone (PAT) monitors\[[@ref16][@ref17]\] have been developed for the evaluation of OSA. Of these, portable monitors have been evaluated and accepted for selected patient groups in clinical guidelines in various countries.\[[@ref18][@ref19]\]

This article reviews recent guidelines and published literature on the clinical use of portable monitoring devices to diagnose OSA and attempts to define the role of portable monitors, especially in high-disease burden, resource poor settings.

Materials and Methods {#sec1-2}
=====================

A search of the available literature was done using the keywords "portable monitoring in obstructive sleep apnea" with filters over last 10 years in humans. The Medline search generated 125 results over the last 10 years. This included 2 systematic reviews and meta-analysis, 3 guideline statements, 16 review articles, 16 randomized controlled trials, and 24 validation studies. Sixty-four articles included expert opinions and cross-sectional studies. In addition, the search was supplemented with data from cross references cited in the bibliography of relevant articles.

The present review has been organized into the following sections:

Introduction and modes of portable monitoring.PMs: Review of the literature.Adaptability of available guidelines for PM in an Indian setting.

Introduction and Modes of Portable Monitoring {#sec1-3}
=============================================

Sleep testing devices were initially classified by the American Academy of Sleep Medicine into level 1 to level 4 devices based on the type of leads and setting of the device used\[[@ref20]\] \[[Table 1](#T1){ref-type="table"}\]. Among these, portable monitoring devices were categorized as level 2, level 3, and level 4 sleep monitoring devices. These monitors have limited number of channels and are used for the diagnosis of certain sleep disorders such as OSA, insomnia, and restless legs syndrome. Recent technical advances have resulted in the design of a variety of compact PM devices that are battery-operated and easy to hook up (wearable). Many of these devices also have wireless monitoring capability. These devices are being proposed as feasible options for out-of-lab diagnosis of OSA. The various modes for portable sleep monitoring based on location, type of sleep study, and technician attendance have been depicted in [Table 2](#T2){ref-type="table"}. However, there are various models of such out of center (OOC) devices, incorporating different combinations of sensors for monitoring. Hence, a blanket acceptance or rejection of such devices has been a problem faced by sleep societies around the world. Recently, a system has been introduced categorizing these devices based on measurements of sleep, cardiovascular, oximetry, position, effort, and respiratory (SCOPER) parameters.\[[@ref21]\] Using the SCOPER categorization, available PM devices with appropriate literature and validation studies have been categorized into a common scheme and devices are judged on whether they can produce a likelihood ratio (LR+) of at least 5 and a sensitivity of at least 0.825 at an in-laboratory apnea-hypopnea index (AHI) of 5.\[[@ref21]\]

###### 

AASM classification of sleep study equipment\[[@ref20]\]

  --------- ---------------------------------------------------------------------
  Level 1   Full-attended polysomnography (≥7 channels) in a laboratory setting
  Level 2   Full-unattended polysomnography (≥7 channels)
  Level 3   Limited channel devices (usually using 4-7 channels)
  Level 4   1 or 2 channels usually using oximetry as one of the parameters
  --------- ---------------------------------------------------------------------

###### 

Modes of portable sleep monitoring

  Type of sleep monitoring   Study site                  Hookup
  -------------------------- --------------------------- ------------
  Attended                   Hospital/sleep laboratory   Technician
  Home                       Technician                  
  Unattended                 Hospital/sleep laboratory   Technician
  Home                       Patient/technician          

Portable Monitors: Review of Literature {#sec1-4}
=======================================

PMs have been used as diagnostic tools for OSA for over two decades.\[[@ref22]\] Several of these devices have been compared with the gold standard PSG in patients with suspected OSA. However, there is a paucity of data comparing the available PM devices with one other. Some of the PMs that have been validated against PSG include ApneaLink,\[[@ref23]\] Edentec,\[[@ref24][@ref25][@ref26]\] PolyG,\[[@ref27]\] AutoSet,\[[@ref28][@ref29][@ref30][@ref31][@ref32]\] Embletta,\[[@ref33]\] Sibel home,\[[@ref34]\] Bedbugg,\[[@ref35]\] NovaSom,\[[@ref36]\] WatchPAT,\[[@ref37][@ref38][@ref39][@ref40]\] SNAP,\[[@ref41]\] SOMNOcheck,\[[@ref42]\] Stardust II,\[[@ref43]\] Apnomonitor,\[[@ref44]\] and Apnea Risk Evaluation System (ARES)\[[@ref45]\] \[[Table 3](#T3){ref-type="table"}\]. The results of the studies conducted with some of these devices are discussed in detail below.

###### 

Studies conducted for validation of various PM devices

  PM device                               Studies (authors, year)                       No. of patients                                                                                                                                                                                                                                           Salient results
  --------------------------------------- --------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Apnea Link™                             Chen *et al*.^\[[@ref23]\]^ (2008)            50                                                                                                                                                                                                                                                        ApneaLink demonstrated the best agreement with laboratory PSG data at cutoff of AHI ≥10. No significant difference between PSG and ApneaLink AHI.
  Milton^\[[@ref46]\]^ (2007)             59                                            ApneaLink AHI compared with AHI from simultaneous PSG at all AHI levels, with the best results at AHI of ≥15/h (sensitivity 91%, specificity 95%).                                                                                                        
  Edentec                                 Redline *et al*.^\[[@ref24]\]^ (1991)         31                                                                                                                                                                                                                                                        High level of agreement between PM and PSG -- AHI, RDI (*r*=0.96) using RDI cutoff of \>10
  Whittle *et al*.^\[[@ref25]\]^ (1997)   23                                            Faster time to diagnosis, lesser cost using PM                                                                                                                                                                                                            
  Oxyflow™                                Jimenez Gomez *et al*.^\[[@ref26]\]^ (2000)   62                                                                                                                                                                                                                                                        RDI obtained by level 1 PSG and PM had comparable areas under ROC\* curve (0.90 for AHI ≥10; 0.94 for AHI ≥15 and 0.96 for AHI \> or 30)
  PolyG™                                  Man^\[[@ref27]\]^ (1995)                      104                                                                                                                                                                                                                                                       Apnea index (AI) correlation -- 0.94; AHI correlation: 0.97; sensitivity -- 82.6%, specificity -- 91.4%.
  Embletta                                Dingli *et al*.^\[[@ref33]\]^ (2003)          101(40 synchronous, 61 home studies compared with PSG)                                                                                                                                                                                                    In the home study, the mean difference in AHI between PSG AHI and Embletta AHI was 3/h 29/ 61 (47.5%) required further investigation. 42% saving in diagnostic costs over polysomnography with a screening study with Embletta
  Sibel home 300™                         Ballester^\[[@ref34]\]^ (2000)                116                                                                                                                                                                                                                                                       At AHI cutoff of 10 on full PSG, sensitivity of the PM was 95% and specificity was 92% At AHI cutoff of 30/h, sensitivity was 100% and specificity was 97%
  Apnea Risk Evaluation System (ARES)     Westbrook^\[[@ref45]\]^ (2005)                299                                                                                                                                                                                                                                                       A diagnostic AHI cutoff of \>10, in-laboratory PSG yielded a sensitivity of 97.4%, specificity of 85.6%, PPV\*\* of 93.6%, and NPV\*\*\* of 93.9% while with the ARES the sensitivity, specificity, PPV and NPV were 91.5%, 85.7%, 91.5%, and 85.7%, respectively
  Somnocheck                              OAC tonelli^\[[@ref42]\]^ (2009)              157                                                                                                                                                                                                                                                       Compared to PSG for detecting AHI \>5, the laboratory-PM demonstrated sensitivity of 95.3% and specificity of 75% while the home-PM exhibited sensitivity of 96% and specificity of 64%.
  Stardust II                             Santos Silva^\[[@ref43]\]^ (2009)             80                                                                                                                                                                                                                                                        Strong correlation between AHI from Stardust II and PSG recordings (*r*\>0.87)
  Watch PAT 100 (PAT signal Device)       Bar *et al*.^\[[@ref37]\]^ (2003)             102                                                                                                                                                                                                                                                       PAT-RDI highly correlated with the PSG-RDI (*r*=0.88, *P*\<0.0001). RDI scores were highly reproducible with high correlation between home and in-laboratory sleep studies (*r*=0.89, *P*\<0.001).
  Zou^\[[@ref40]\]^ (2006)                98                                            RDI, AHI, and ODI with Watch PAT 100 correlated closely (0.88, 0.90, and 0.92; *P*\<.0001, respectively) with the corresponding indices obtained by PSG. The agreement of sleep-wake assessment based on 30-s bins between the 2 systems was 82 +/-- 7%   
  AutoSet CPAP (ResMed)                   Fleury *et al*.^\[[@ref29]\]^ (1996)          44                                                                                                                                                                                                                                                        AutoSet overestimated the number of apneas. Correlation between the AI assessed by PSG and AutoSet (*r*=0.98). For an AI of 20/h the AutoSet was 100% sensitive and 88% specific. AutoSet AHI and the AHI -- PSG: *r*=0.92; *P*\<0.001. AutoSet PPV -- 86%
  Kiely *et al*.^\[[@ref30]\]^ (1996)     36                                            AutoSet detection of AHI-PSG \>20: Sensitivity 97%, specificity of 77%.                                                                                                                                                                                   
  Gugger^\[[@ref31]\]^ (1997)             67                                            Mean difference between the AHI-AutoSet minus the AHI-PSG was 4.2 /h(SD 7.2) (*P*\<0.001)                                                                                                                                                                 
  Mayer *et al*.^\[[@ref32]\]^ (1998)     95                                            AHI assessed by AutoSet and PSG: *r*--0.87, *P*\<0.0001, sensitivity -- 92%, specificity -- 79%, PPV -- 93%, NPV -- 76%.                                                                                                                                  

\*ROC: Receiver operating characteristic, \*\*PPV: Positive predictive value, \*\*\*NPV: Negative predictive value

Studies conducted to validate PM {#sec2-1}
--------------------------------

Level 4 devices are the simplest forms of PMs and consist of a nasal cannula to monitor airflow and a finger probe to record oxygen saturation. Milton *et al*. evaluated the sensitivity and specificity of a Level 4 device, the ApneaLink™\[[@ref46]\] (ResMed Corporation) as a screening tool for sleep apnea. The AHI obtained using this device in the laboratory and at home was compared to attended sleep-laboratory PSG in fifty-nine patients with type 2 diabetes mellitus. The study demonstrated a high sensitivity and specificity (91% and 95%, respectively) of the at-home ApneaLink AHI with the simultaneous PSG at all AHI levels, the best results being at an AHI of ≥15 events/h. The AHI comparison from the home and laboratory PM studies also demonstrated good sensitivity and specificity at AHI levels of ≥15 and ≥20 events/h (sensitivity 76% and specificity 94% for both).

The same device was also compared with a level 1 device (Alice 4) for diagnostic accuracy by Ng *et al*.\[[@ref47]\] in 50 patients with suspected OSA. They observed a close correlation (*r* = 0.978) between AHI obtained by the two devices at AHI \>10/h as well as \>20/h. Further, the correlation between PSG AHI and oxygen desaturation index by ApneaLink was strong (*r* = 0.895) thereby drawing the conclusion that the ApneaLink device was highly sensitive and specific in quantifying AHI for screening and diagnostic purposes when access to PSG was limited.

Another level 3 sleep monitor, Apnoeascreen II (hooked up by a technician) was compared with in-laboratory PSG by Quintana-Gallego *et al*.\[[@ref48]\] in 75 patients with stable heart failure. Using AHI cutoff points of \>5, \>10, and \>15, the authors generated diagnostic accuracies of 78.6%, 84%, and 80%, respectively. However, they reported an overall diagnostic failure rate of 8% in home studies.

While validation studies of several such monitors have been conducted, most studies comprised a small number of subjects. The details of studies performed with such devices are summarized in [Table 3](#T3){ref-type="table"}.

In-Laboratory Versus Home Sleep Studies {#sec1-5}
=======================================

Home sleep studies have been evaluated with simultaneous in-laboratory PSG by many researchers. Iber *et al*.\[[@ref48]\] compared in-laboratory and home monitoring in 76 participants using a level 2 device (Compumedics, Australia) using the Sleep Heart Health Study (SHHS) methodology. They reported that the median sleep time and sleep efficiency were better in home sleep studies. Further, median RDI values were comparable between at-home and in-laboratory measurements. They suggested that patients with an RDI \<20 were more likely to be diagnosed in the laboratory when compared to those with RDI \>20. The misclassification rate in home studies was 22% and was hypothesized as being due to night-to-night variability of OSA. Other studies\[[@ref48][@ref49][@ref50][@ref51][@ref52]\] have also highlighted the night-to-night variability ranging from 10% to 20% in attended as well as unattended studies.

Dingli *et al*.\[[@ref33]\] evaluated synchronous recording with PM and traditional in-laboratory PSG followed by a home sleep study with the Embletta device (Flaga, Iceland), a level 3 monitor. The home-based studies showed an overall good agreement with laboratory-based PSG outcomes (kappa coefficient: 0.54; *P* -- 0.001). Apart from this, home screening resulted in 42% saving in diagnostic costs. Thus, home monitoring was suggested as a reliable and cost-effective method for screening in patients with suspected OSA.

The AASM guideline published in 2007 defines indications for unattended portable monitoring in specific patient populations with high suspicion of OSA.\[[@ref53]\] According to the Indian Initiative on Obstructive Sleep Apnea (INOSA) guidelines, a laboratory-attended PSG is not necessary in all patients suspected to have OSA. Portable monitoring or out of center testing (OCST) with type 3 or type 4 devices (that should at least include airflow, oxygen saturation, and respiratory effort) is adequate for diagnosis. This is acceptable in conjunction with comprehensive sleep evaluation and in patients with high pretest probability of moderate to severe OSA without comorbid sleep disorders or medical disorders such as pulmonary disease, neuromuscular disease, or congestive heart failure.\[[@ref18]\]

According to INOSA guidelines, comprehensive evaluation and assessment of pretest probability can be performed using questionnaires such as Epworth Sleepiness Scale (ESS), Berlin questionnaire, modified Berlin questionnaire and STOP-BANG questionnaire. Out of these, STOP-BANG is the most recommended screening tool before portable monitoring due to the ease of administration and high sensitivity.

PM and CPAP Prescription {#sec1-6}
========================

Although several comparative studies between PM and level 1 sleep studies have demonstrated a high sensitivity for PM, it is noteworthy that these studies predominantly concentrate on diagnostic accuracy and reliability. Translation of results derived from PM into continuous positive airway pressure (CPAP) prescription is an important consideration. This is especially important in settings where low cost home testing is a preferable alternative to in-laboratory PSG. Some prospective studies pertaining to this aspect of portable monitoring have been discussed below.

Rafael and coworkers\[[@ref54]\] studied 55 patients wherein a therapeutic decision (use of CPAP) made with unattended PM device was compared with that made after a subsequent PSG. Patients were equally subdivided into the technician hookup (group 1) and self-hookup groups (group 2) at the time of initial PM monitoring. The authors reported that 16% of the recordings among the home study group were inconclusive. In 75% of the interpretable home studies, the diagnosis was seen to correlate with in laboratory PSG; this figure rose to 89% on exclusion of inconclusive home studies. Among the two subsets of home study, data were not interpretable due to artifacts in 7% of the patients in group 1 and 33% in group 2 (*P* \< 0.05). CPAP decision disagreement between home and lab studies occurred in about one third of patients. Cost effectiveness analysis showed reduction in study costs at home compared to in lab study. Thus, this study projected home sleep studies with technician hook-up as a viable diagnostic modality to decide about CPAP prescription.

In a similar study, Parra *et al*.\[[@ref55]\] tested 89 patients with suspected OSA in two settings, in the sleep laboratory using level 1 sleep study and at the patient\'s home using a portable monitor. In the latter setting, 50 patients were assisted by a technician and 39 patients set up the equipment themselves. An acceptable agreement was obtained between the AHI measured by full-PSG and PM. The clinical therapeutic decision taken after PM agreed with that taken with full-PSG in 89% of patients. Apart from this, the domiciliary studies were about three times less costly than level 1 PSG. They concluded that patients with suspected OSA should initially be studied in a home setting with a PM. Parra *et al*.\[[@ref55]\] also noted that patients who were located far away from the hospital frequently preferred to be studied in the laboratory than at home. These findings were further validated by other studies.\[[@ref56]\] However, in contrast there are two studies with a similar design that have found a higher frequency of unacceptable studies with PMs.\[[@ref25][@ref57]\] The discrepancy with respect to error rates and acceptability of PMs among the various studies cited above can be explained in relation to the differences in technical specifications, data analyzed, sensors used in various PM devices, diverse patient groups and preferences, and study setting and availability of technicians for hookup at home.

Since continuous positive airway pressure can be titrated most effectively with monitoring in a sleep laboratory,\[[@ref58]\] an attended in-laboratory CPAP titration study/split night study was also necessary conventionally after a diagnosis of OSA was made. However, nowadays the validation and clinical use of the auto-titrating PAP device minimizes the need for an in-laboratory titration study for patients with moderate to severe OSA. This is feasible since these devices can be used in an unattended way to determine fixed CPAP treatment pressure for such patients who do not have significant co morbidities such as congestive cardiac failure, chronic obstructive pulmonary disease, central sleep apnea syndrome, and hypoventilation syndrome.\[[@ref59]\]

Further, in patients with more than one sleep disorder such as OSA and insomnia, in patients with problems such as overlap syndrome (where suboptimal levels of CPAP can actually worsen hypoxia) as well as patients underdiagnosed by PM, home studies may be followed by repeat type I test. Apart from this, knowledge of autotitrating CPAP devices may not be uniform, especially with respect to known contraindications in certain special populations (heart failure), limitations (nasal obstruction), and variability in device performance, and air leak between manufacturers.\[[@ref60]\]

Portable Monitoring: The Indian Scenario {#sec1-7}
========================================

As opposed to the global data described above, awareness about sleep disorders and scientific research in sleep medicine in the Indian subcontinent has demonstrated a gradual upward trend only since the past two decades. The paucity of trained sleep technologists and physicians, financial considerations, and an unknown disease burden has led to a widespread use of PMs in both clinical and research settings. In a study by Udwadia *et al*.,\[[@ref61]\] the prevalence of OSA was estimated using technician hookup-based PM (Compumedics P series). OSA prevalence in middle-aged urban Indian men was estimated to be 19.5%.

Portable Monitors: Summary of Available Literature {#sec1-8}
==================================================

It is evident from the literature reviewed in the preceding paragraphs that there is considerable heterogeneity in the applicability and modes of portable monitoring for the diagnosis of OSA.

However, there is compelling evidence to suggest that home sleep studies have evolved as a viable and more economical mode of diagnosing OSA worldwide. When equipment with multiple channels are used, the involvement of a sleep technician for hookup in the patient\'s home has been shown to be a good intervention to improve the accuracy and reliability of testing. The inferred merits and demerits of PM are summarized in [Table 4](#T4){ref-type="table"}.

###### 

Merits and demerits of portable sleep monitoring

  ---------------------------------------------------------------------------------------------------------
  Merits of portable monitors
   Can resolve problems related to accessing sleep clinics and laboratories
   Reduction in costs and waiting times for level 1 and level 2 sleep studies
   May obviate the need for exhaustive testing when OSA is strongly suspected
   Comfort and convenience of sleeping at home ensures less disruption of sleep
   Feasible option for patients with limited mobility
  Demerits of portable monitors
   Patient self-hookup/unattended study may affect data quality
   Variability owing to diversity in devices and scoring schemes
   Non-OSA sleep disorders, occult seizures and cardiac arrhythmias may be missed
   Lack of EEG channels precludes sleep staging, thus affecting accuracy of grading severity if it is OSA
  ---------------------------------------------------------------------------------------------------------

\*EEG: Electroencephalography

Adaptablity of Available Guidelines for PM in Indian Setting {#sec1-9}
============================================================

Practice parameters for PSG were first published by the American Sleep Disorders Association in 1994.\[[@ref20]\] On the basis of the then available literature on PM, these guidelines considered that PM had inadequate sensitivity for routine diagnostic testing. Subsequent to these guidelines, several systematic reviews and meta-analyses regarding the use of portable devices were published.

In 2007, the American Academy of Sleep Medicine (AASM) updated practice parameters for the use of unattended PMs in the diagnosis of OSA in adult patients and since its publication, further studies have already been conducted adding to the pool of evidence. The major recommendations in this statement are hereby reviewed in the context of their adaptability in the Indian setting \[[Table 5](#T5){ref-type="table"}\]. Recently published Indian guidelines (INOSA) accept PM (type 3 and 4) as a useful, cost-effective, convenient, and speedy method of diagnosis after careful patient selection and by a trained sleep physician.

###### 

Summary of major recommendations by AASM with adaptability in India

  AASM recommendation                                                                                                                                Adaptability in India
  -------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Unattended portable monitoring should be performed only in conjunction with comprehensive sleep evaluation                                         In view of the unexplored OSA burden, complete sleep evaluation with portable monitoring may be acceptable
  Sleep evaluations using PM must be supervised by a board certified practitioner                                                                    Number of trained sleep specialists needs to be increased
  PM may be used as an alternative for diagnosis of OSA in patients with high pretest probability of moderate-to-severe OSA                          As lack of awareness has led to patients being diagnosed at the severe end of the OSA spectrum, pretest probability is naturally high, favoring portable monitoring
  PM is not appropriate for patients with significant comorbid medical conditions                                                                    Use of level 1 PSG could be reserved for patients suspected of having non-OSA/multiple sleep disorders
  PM is not appropriate for a general screening of asymptomatic populations                                                                          PM can be used in high-risk populations/to determine the prevalence of OSA
  PM may be indicated when in-laboratory PSG is not possible due to immobility/critical illness/monitoring response to non-CPAP treatments for OSA   Due to paucity of sleep laboratories and trained personnel, PM may be undertaken in a hospital ward or at home
  PM must record at least the airflow, respiratory effort, and blood oxygenation using conventional biosensors                                       Use of standardized equipment may facilitate screening of more patients
  PM must allow for display of raw data with the capability of manual scoring or editing of automated scoring by a qualified sleep technician        With the right device and a trained technician, PM can be used in resource poor settings

A flowchart to guide selection of patients for portable sleep studies is depicted in [Figure 1](#F1){ref-type="fig"}.

![Flowchart to guide PM selection](JPGM-61-223-g001){#F1}

Conclusion {#sec1-10}
==========

A detailed evaluation for pretest probability (risk stratification, screening with sleepiness scales, and clinical exam, especially upper airway evaluation) in conjunction with portable monitoring has been recommended to obviate the need for level 1 and level 2 sleep studies in patients with OSA. This holds special importance, especially in resource poor settings. The published practice parameters for PM are relevant and applicable in the Indian setting. In conclusion, a greater adoption of PMs by trained sleep physicians would enable the timely diagnosis of OSA with reduced cost and waiting time.
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